Cargando...
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of ≥3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated wi...
Gardado en:
| Publicado en: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734313/ https://ncbi.nlm.nih.gov/pubmed/26893783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.4069 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|